1. Administration, U. F., & a., D. (2010). FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety.
2. Administration, U. F., & a., D. (2012). FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. June 15, 2011.
3. Ahn, J. H., Seo, H., Park, W., Seok, J., Lee, J. A., Kim, W. J., Kim, G. B., Kim, K. J., & Lee, S. Y. (2020). Enhanced succinic acid production by Mannheimia employing optimal malate dehydrogenase. Nature communications, 11(1), 1970.
4. Al Sultan, A., Rattray, Z., & Rattray, N. J. (2023). Cytotoxicity and Toxicoproteomic Analysis of Pioglitazone Exposure in Human-derived Cardiomyocytes.
5. Toxicometabolomics-based cardiotoxicity evaluation of Thiazolidinedione exposure in human-derived cardiomyocytes;Al Sultan A;Metabolomics,2024